Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial

European Urology

Volumn 44, Issue 4, 2003, Pages 429-434

  Van der Meijden, Adrian P M ^a   Sylvester, Richard J ^b   Oosterlinck, Wim ^c   Hoeltl, Wolfgang ^d   Bono, Aldo V ^e  

^a JEROEN BOSCH HOSPITAL   (Netherlands)

^b Treatment of Cancer Data Center   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Adverse effects; Bladder neoplasms; Mycobacterium bovis; Transitional cell carcinoma

Indexed keywords

BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ISONIAZID;

ALLERGIC REACTION; ARTHRALGIA; ARTHRITIS; ARTICLE; BLADDER DISEASE; BLADDER IRRITATION; BLADDER TUMOR; CANCER RECURRENCE; CHILL; CLINICAL TRIAL; COMORBIDITY; CONTRACTED BLADDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDIDYMITIS; FEVER; FLU LIKE SYNDROME; HEMATURIA; HUMAN; LIVER TOXICITY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALAISE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; URETER OBSTRUCTION; URINARY FREQUENCY;

EID: 0141460505     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00357-9     Document Type: Article

References (12)

1. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-5.
2. Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
3. Lamm DL, Steg A, Boccon-Gibod L, Morales A, Hanna Jr MG, Pagano F, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989;335-55.
4. Lamm DL, van der Meijden APM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;47:596-600.
5. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino PA. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guérin for transitional cell carcinoma of the bladder. N Eng J Med 1991;325:1205-9.
6. van der Meijden APM, Brausi M, Zambon V, Kirkels W, de Balincourt C, Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder. A European Organization for Research and Treatment of Cancer GU Group randomized phase III trial. J Urol 2001;166:476-81.
7. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol 2000;163:1124-9.
8. Vegt PFJ, van der Meijden APM, Sylvester R, Brausi M, Hoeltl W, de Balincourt C. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guérin therapy in superficial bladder cancer? Interim results of EORTC protocol 30911. J Urol 1997;157: 1246-9.
9. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection versus transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16.
10. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MKB, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996;156:1934-41.
11. Morgia G, Falsaperla M, Madonia M, Vacirca F, La Pira G, De Grande G, et al. Use of BCG in immunotherapy of superficial bladder cancer: multicentric investigation on safety and compliance. UroOncology 2002;2:129-35.
12. Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001;57:883-8.